Last reviewed · How we verify

NCT06861010

Evaluating the Safety and Efficacy of Ondansetron in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis

Recruiting now Phase 3 Last updated 13 March 2026
What this trial tests

Phase 3 trial testing Placebo in Pancreatic Diseases in 44 participants. Currently enrolling.

Timeline
1 March 2025
Primary endpoint
20 December 2026
20 December 2026

Quick facts

Lead sponsorTanta University
PhasePhase 3
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment44
Start date1 March 2025
Primary completion20 December 2026
Estimated completion20 December 2026
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Tanta University

Who can join

Adults 18 to 65, any sex, with Pancreatic Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Endoscopic retrograde cholangiopancreatography (ERCP (, a key tool that is used in diagnosis and treatment of pancreato-biliary diseases. Post-ERCP pancreatitis (PEP) is the most common and serious complication that can occur following this procedure and can lead to significant morbidity and mortality. A variety of patient-related and procedure-related factors have been associated with higher rates of PEP.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Ondansetron

Trials testing the same drug.

Other recruiting trials for Pancreatic Diseases

Currently open trials in the same condition.

Other Tanta University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06861010.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing